PPIDT00445
Drug Information
| Name | Bamlanivimab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB15718 |
| Type | biotech |
| Indication | Bamlanivimab is not currently approved for any indication by the FDA.[L20974] Bamlanivimab is authorized under an Emergency Use Authorization (EUA) for the treatment of mild to moderate COVID-19 in patients aged 12 years and older weighing at least 40 kg who are at high risk for progressing to severe COVID-19 and/or hospitalization due to COVID-19. Patients should have confirmed COVID-19, with identification of SARS-CoV-2 viral load by an approved test.[L20974, L20979] Under this EUA, bamlanivimab is not authorized in patients who are hospitalized due to COVID-19, who require oxygen due to COVID-19, or in patients on oxygen therapy for non-COVID-19-related comorbidity who require an increased oxygen flow rate due to COVID-19.[L20974, L20979] Bamlanivimab in combination with etesevimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. This combination regimen is also used for post-exposure prophylaxis of COVID-19 in unvaccinated or immunocompromised adults and pediatric individuals, including neonates, who are at high risk of progression to severe COVID-19, including hospitalization or death.[L40184] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Intravenous |
35 mg/1mL
|
| Solution | Intravenous |
700 mg / 20 mL
|